Cosibelimab not checked
Checkpoint Therapeutics, Inc. · TG-1501 · CK-301
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Ligand-1 Blocker FDA class
- Tested for
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma and 5 more
- Main trialPhase 1
- “CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.”In the company’s words, NCT03212404 on ClinicalTrials.gov
- Other names
- TG-1501 · CK-301
Other drugs for Lung Neoplasms
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 18 Nov 2021 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | |
| Phase 3Terminated | 30 Dec 2023 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC | |
| Phase 1Completed | 4 Nov 2021 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | |
| Phase 1Terminated | 3 May 2022 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026